Research programme: nitric oxide synthase DNA-based therapeutics - Cardium Therapeutics
Alternative Names: Ad5eNOS; GenvascorLatest Information Update: 24 Mar 2010
At a glance
- Originator Bayer Schering Pharma
- Developer Cardium Therapeutics
- Class
- Mechanism of Action Intercellular signalling peptide and protein stimulants; Nitric oxide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemia
Most Recent Events
- 04 Jul 2007 Preclinical trials in Ischaemia in USA (unspecified route)
- 17 Jul 2002 Schering AG has acquired Collateral Therapeutics